In this article, we will take a look at the 11 Best Stocks to Buy for Investment.
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week. The S&P 500 index rose to a new all-time high as investors await earnings from companies in the tech sector. On January 27, the NASDAQ Composite was up over 0.91%, compared with 0.40% gains for the S&P 500. Tech giants aided the rally on Tuesday, driven by expectations of the Fed rate decision.
The Federal Reserve is expected to keep interest rates unchanged after the conclusion of its two-day policy meeting. CME Group highlighted a 97% chance the Fed will hold rates steady between 3.50% and 3.75%.
After cutting rates three times during 2025, the Fed is once again in a wait-and-see mode, according to Yahoo Finance’s Hal Bundrick. The next rate cut will not occur before June 2026 under the current think tank, according to CME Group. Fed officials have said they will proceed meeting by meeting to shape the policy path.
According to JPMorgan Asset Management, S&P 500 gains are being driven by earnings growth, with tech expected to drive 60% of EPS growth in 2026.
Thomas Martin, senior portfolio manager at Globalt Investments, said:
Everybody is watching anything that gives you insight into the [AI] narrative. It’s all going to be about commentary about that in addition to the amount of money that they’re spending, both on the capex line and the opex line.
Martin added that AI isn’t going away, nor is data center infrastructure. He further mentioned:
The usage of it, the usage of the models, the advent of agents, robotics, etc. — all that stuff is just going to continue its trajectory of discovery. It’s going to be backwards and forwards, but we expect it to be with a positive bias,” Martin said about AI’s market impact.
With that, let’s take a look at the 11 Best Stocks to Buy for Investment.
A person with a cell phone who is looking for new stocks
Our Methodology
To create the list of 11 best stocks to buy for investment, we shortlisted companies with a trailing twelve-month (TTM) EPS growth rate and a forward EPS growth rate of at least 20%, while these companies had a 3-year revenue growth rate of over 20% and a Beta of under 1. We selected only those stocks with upside potential. Finally, we ranked, in ascending order, the 11 best stocks to buy for investment based on the number of hedge funds holding positions in them. The hedge fund sentiment data for each stock were sourced from Insider Monkey’s database as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Note: All the data is as of market close on January 27, 2026.
11. AppFolio, Inc. (NASDAQ:APPF)
Number of Hedge Fund Holders: 40
AppFolio, Inc. (NASDAQ:APPF) is one of the best stocks to buy for investment.
As of January 27, AppFolio, Inc. (NASDAQ:APPF) shares have plunged by over 15% over the past year. However, all analysts covering APPF are bullish on the stock with a median price target of $318. This implies a potential upside of over 47%.
On December 12, TheFly reported that UBS initiated coverage of AppFolio, Inc. (NASDAQ:APPF) with a Buy rating, setting the price target at $285. Seth Gilbert at UBS believes AppFolio’s channel checks indicate no signs of a spending slowdown or rising competitive pressure, according to TheFly. Gilbert also pointed out that their analysis indicates healthy demand for its core product and incremental traction upselling with APM Plus and Max.
In other news, on January 15, D.A. Davidson reiterated a Buy rating on AppFolio, Inc. (NASDAQ:APPF), keeping the price target at $325. D.A. Davidson’s analyst Clark Wright retains a positive view on APPF following Bilt’s announcement of its 2.0 Credit Cards Program. Bilt 2.0 introduced a revised reward system for cardholders, which comes with a potential churn risk, added Wright. The analyst sees this as a great competitive opportunity for AppFolio to design its own offering that could be a suitable option compared to the competitor.
AppFolio, Inc. (NASDAQ:APPF) is a cloud-based property management software provider. The company, along with its subsidiaries, assists real estate clients from leasing to maintenance and accounting in the U.S.
10. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Number of Hedge Fund Holders: 41
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best stocks to buy for investment.
On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond oncology. The analyst expects these deals to help ENHANZE reach into large and durable markets such as inflammatory bowel disease and obesity.
In other news, on January 8, Morgan Stanley slightly lowered the price target on HALO from $79 to 75, keeping an Overweight rating. The analyst at Morgan Stanley expects small-to-mid-cap U.S. biotech stocks to outperform in 2026 as commercial names shift from ‘capital consumers to producers.’ The analyst sees large-cap biopharma companies facing a looming patent cliff.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on the research, development, and commercialization of proprietary enzymes and devices worldwide.
9. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)
Number of Hedge Fund Holders: 42
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is one of the best stocks to buy for investment.
On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating. Swayampakula Ramakanth from H.C. Wainwright has increased the price target on MIRM twice in a span of two weeks.
Ramakanth’s price target revisions are based on Mirum’s bullish guidance for 2026. The analysts see 2026 to be a vital year for volixibat as clinical evaluation enters into two chronic immune-mediated cholestatic liver diseases. The analyst believes that volixibat could launch as early as the first half of 2027. The company expects the Volixibat VISTAS study in primary sclerosing cholangitis topline data in the second quarter of 2026, while enrollment for the study is expected to be completed in the second half of 2026.
Over the past six months, as of January 27, MIRM shares have skyrocketed over 91%. All 11 analysts covering Mirum Pharmaceuticals rate the stock a Buy, with the median price target set at $103, implying a slight upside of just under 4%. Ramakanth’s price target of $130 implies an upside potential of almost 31%.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a biopharmaceutical firm that engages in the development and commercialization of therapies for debilitating rare and orphan diseases.
8. TKO Group Holdings, Inc. (NYSE:TKO)
Number of Hedge Fund Holders: 42
TKO Group Holdings, Inc. (NYSE:TKO) is one of the best stocks to buy for investment.
On January 21, TheFly reported that JPMorgan increased the price target on TKO Group Holdings, Inc. (NYSE:TKO) from $220 to $225, maintaining an Overweight rating. David Karnovsky from JPMorgan raised the price target as he updated TKO’s model ahead of the Q4 2025 release. Karnovsky sees long-term compounded FCF growth potential at TKO Group Holdings.
In another analyst price raise on TKO on January 19, Joseph Stauff from Susquehanna raised the price target from $230 to $251. Stauff lifted the price target on TKO Group as he sees upside to the company’s 2026 earnings estimate. The analyst believes that greater sponsorship and live-event shifts toward locations with site-fee benefits, along with cross-marketing events, are crucial value drivers for the company.
TKO Group Holdings, Inc. (NYSE:TKO) is a sports and entertainment company. The company owns and manages sports and entertainment intellectual property and is engaged in organizing live events and creating long-form and short-form content. The company owns WWE and UFC.
7. Mirion Technologies, Inc. (NYSE:MIR)
Number of Hedge Fund Holders: 44
Mirion Technologies, Inc. (NYSE:MIR) is one of the best stocks to buy for investment.
Over the past year, as of January 27, Mirion Technologies, Inc. (NYSE:MIR) shares have soared over 73%. Of the 9 analysts covering MIR, 89% rate the stock a Buy, while 11% rate it a Hold. MIR has a median price target of $29, which implies an upside potential of almost 14%.
On January 23, TheFly reported that Morgan Stanley initiated coverage of Mirion Technologies, Inc. (NYSE:MIR) with an Equal Weight rating, setting the price target at $29.
Christopher Snyder at Morgan Stanley initiated coverage of MIR, believing the company will benefit from additional global nuclear power generation capacity driven by growing data centers and rapid adoption of new technologies. Snyder pointed out that Wall Street is ‘well-calibrated for this optimism’ and ‘positive revisions will be hard to come by,’ keeping in mind MIR’s ‘premium valuation.’
TimesSquare Capital U.S. Small Cap Growth Strategy stated the following regarding Mirion Technologies, Inc. (NYSE:MIR) in its third quarter 2025 investor letter:
Joining the strategy this quarter was Mirion Technologies, Inc. (NYSE:MIR), which manufactures radiation detection, measurement, and monitoring products serving nuclear power and medical applications. Its nuclear power solutions are used in over 95% of the world’s nuclear reactors while its medical products have a presence in 80% of the world’s cancer centers. The recent acquisition of Paragon Energy Solutions provides Mirion with additional safety-related offerings for nuclear power plants and provides Mirion with greater relevance to the small modular reactor (SMR) market via design wins with well-capitalized SMR manufacturers.
Mirion Technologies, Inc. (NYSE:MIR) offers radiation detection, measurement, analysis, and monitoring products and services globally. The company operates via two segments: Medical and Nuclear & Safety.
6. Ascendis Pharma A/S (NASDAQ:ASND)
Number of Hedge Fund Holders: 49
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best stocks to buy for investment.
On January 27, BofA reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND). Tazeen Ahmad at BofA retained the rating on ASND and maintained the price target at $246.
In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating on the stock. Archila noted Ascendis Pharma’s €500 million operating cash flow guidance, excluding TransCon CNP, implying €1.1- €1.2 billion for Yorvipath. The analyst said this is in line with the company’s forecast of €40 million to €50 million in quarter-over-quarter revenue growth.
Archila believes that the TransCon CNP with the Skytrofa combo will potentially become the standard of care over time, representing upside for the company. Skytrofa is being used for the treatment of pediatric growth hormone deficiency, while TransCon is being developed for achondroplasia.
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical firm developing TransCon-based therapies to address unmet medical needs worldwide.
5. Argenx SE (NASDAQ:ARGX)
Number of Hedge Fund Holders: 50
Argenx SE (NASDAQ:ARGX) is one of the best stocks to buy for investment.
On January 20, TheFly reported that Wells Fargo increased the price target on Argenx SE (NASDAQ:ARGX) from $1,264 to $1,317, keeping an Overweight rating on the shares.
Derek Archila from Wells Fargo raised the price target on ARGX following its strong outlook on Argenx’s Vyvgart, according to TheFly. Archila has raised the 2026-2030 Vyvgart outlook by 5-15%. Vyvgart is an antibody used to treat severe autoimmune diseases, such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
The analyst believes Argenx SE’s FY2026 consensus estimate of $5.6 billion is too low given the growth trajectory. Archila expects the company to generate approximately $6.5 billion, considering single-digit quarter-over-quarter growth in Q1 FY2026 and low double-digital quarter-over-quarter growth between Q2 and Q4. Wall Street’s consensus estimate of $1.18 billion for Q1 indicates a growth of almost 65.79% from a year ago.
Over the past six months, Argenx SE’s shares have soared by over 45% as of January 27. Out of 28 analysts covering ARGX, 86% rank the stock as a Buy. ARGX has a median price target of $1,007.86, representing an upside of 16.80%.
Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company. Argenx is developing therapies to treat autoimmune diseases.
4. Rubrik, Inc. (NYSE:RBRK)
Number of Hedge Fund Holders: 52
Rubrik, Inc. (NYSE:RBRK) is one of the best stocks to buy for investment.
As of January 27, Rubrik shares have soared by more than 41% over the past six months. 25 of 24 analysts covering RBRK rate the stock a Buy, with a median price target of $110. This represents a potential upside of over 71%.
On January 15, the company announced the launch of Rubrik CXO Visionaries. Rubrik has created an exclusive community that brings Fortune 500 and Enterprise 2000 CIOs, CISOs, and CTOs together to secure and accelerate global AI transformation.
Rubrik is focusing on the control layer’s response to growing cyber and AI-driven security threats. The company reported that 90% of IT and security leaders experienced a cyberattack in the past year, and 58% expect agentic AI to drive nearly half of attacks this year, according to Rubrik Zero Labs research. The CTO at Rubrik, Kavitha Mariappan, said:
Today’s CXOs are operating at the intersection of security, privacy, compliance, and innovation — where decisions directly shape competitive advantage and trust. Yet confidence in resilience is declining. Rubrik Zero Labs found that in 2025, only 28% of organizations believe they can fully recover from a cyber incident in 12 hours or less, down from 43% in 2024. By bringing leaders across cybersecurity and AI together, we’re enabling practical insight and clearer decision-making for what comes next.
Rubrik CXO Visionaries will offer tech leaders with peer insights, strategic influence, and a trusted network to security, compliance, and AI risks. This will allow leaders to anticipate attacks as cyber resilience becomes a major part of business requirements.
In other news, on January 12, TheFly reported that KeyBanc lowered its price target on Rubrik, Inc. (NYSE:RBRK) from $113 to $95 while maintaining an Overweight rating. KeyBanc’s Eric Heath’s latest update on the stock indicates a slight contraction in peer valuation multiples and a more cautious outlook on enterprise security spending.
Rubrik, Inc. (NYSE:RBRK) offers data security solutions to enterprises and individuals worldwide. The company provides unstructured data protection, cloud data protection, SaaS data protection solutions, and other data protection layers against cyber and AI threats.
3. Agnico Eagle Mines Limited (NYSE:AEM)
Number of Hedge Fund Holders: 57
Agnico Eagle Mines Limited (NYSE:AEM) is one of the best stocks to buy for investment.
On January 23, TheFly reported that Canaccord Genuity raised the price target on Agnico Eagle Mines Limited (NYSE:AEM) from $224.33 to $252.10. Carey MacRury at Canaccord maintained his Buy rating on AEM while raising the price target.
In other news, on January 19, TheFly reported that Lawson Winder at BofA raised the price target on Agnico Eagle Mines Limited (NYSE:AEM) from $227 to $252, while keeping his Buy rating on the stock. Winder has increased price targets across the North American precious metals group. The analyst pointed out that many of the macro drivers that lifted gold prices have intensified.
Winder expects Agnico Eagle Mines to post strong capital returns in Q4, along with other precious metals firms. The company is scheduled to report its quarterly results on February 12, 2026, with Street expecting an average EPS of $2.64, up from $1.26 from a year ago. The revenue is estimated to be around $3.44 billion, indicating a remarkable growth of over 54% year-over-year.
Agnico Eagle Mines Limited (NYSE:AEM) is a gold mining company that explores for precious metals. The company is engaged in the development and production of gold, silver, zinc, and copper.
2. Grab Holdings Limited (NASDAQ:GRAB)
Number of Hedge Fund Holders: 59
Grab Holdings Limited (NASDAQ:GRAB) is one of the best stocks to buy for investment.
On January 16, TheFly reported that HSBC upgraded Grab Holdings Limited (NASDAQ: GRAB) from Hold to Buy, with a price target of $6.20. Piyush Choudhary at HSBC raised the rating on GRAB, citing an attractive valuation following the recent selloff and lower Wall Street expectations, according to TheFly.
Choudhary believes that Grab Holdings Limited’s growth drivers are intact. As the company strengthens its leadership position, it will continue to roll out innovative and affordable products, the analyst added.
Over the past five days, GRAB shares have soared nearly 4.99%, as of writing on January 27. GRAB shares outperformed the market in today’s trading session, rising 2.85%, exceeding the S&P 500 index’s 0.41% and the Nasdaq’s 0.91% gains. Of the 30 analysts covering the stock, 28 rate it a Buy, with a median price target of $6.95. This indicates an upside potential of more than 46.50%. Ahead of its Q4 2025 earnings on February 12, investors have their eyes on GRAB shares. Wall Street expects the company to post an EPS of $0.01 during Q4 2025, which is lower than $0.02 from a year ago. The average estimate for the revenue is around $940.60 million, which indicates year-over-year growth of over 23%.
Grab Holdings Limited (NASDAQ:GRAB) provides superapps in Southeast Asia. The company operates across four segments: Deliveries, Mobility, Financial Services, and Others.
1. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Number of Hedge Fund Holders: 72
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best stocks to buy for investment.
On January 11, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) unveiled its new five-year strategy, ‘Alnylam 2030.’ The company shared its plans to scale operations, focus on durable leadership in transthyretin (TTR) amyloidosis, and deliver sustained, profitable growth.
Alnylam Pharmaceuticals is targeting to lead the global TTR market and generate revenue through 2030. TTR is a protein disorder that starts building irregular proteins known as fibrils in your heart, making it hard for the heart to pump blood to the body. The company plans to launch next-generation RNAi silencer nucresiran in polyneuropathy by 2028 and cardiomyopathy by 2030. In addition to other research and product goals, the company aims to achieve a revenue CAGR of over 25% through 2030 and to reach a non-GAAP operating margin of nearly 30%.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) projects its 2026 combined net product revenue to be between $4.9 billion and $5.3 billion. The majority of the revenue is expected from TTR, while the Rare segment revenue is expected to be around $500-$600 million. On January 12, TheFly reported that Needham analyst Joseph Stringer increased the price target on Alnylam Pharmaceuticals from $520 to $529, keeping a Buy rating. Stringer remains positive on ALNY following the company’s promising FY2026 outlook. The analyst sees Alnylam’s Amvuttra launch in TTR-CM to be a major catalyst for the stock in 2026, citing that the initial revenue guidance looks highly encouraging and has additional room for upside.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biotech firm that discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. The company’s core focus is to develop transformative therapies to prevent or reverse disease.
While we acknowledge the potential of ALNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 12 Best Commodity Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
